{"classes":[{"categories":[{"measurements":[{"comment":"More than 50% patient was censored.","groupId":"OG000","lowerLimit":"2.6","upperLimit":"NA","value":"6.5"},{"comment":"More than 50% patient was censored.","groupId":"OG001","lowerLimit":"1.4","upperLimit":"NA","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with hodgkin lymphoma","id":"OG000","title":"Cohort 2"},{"description":"Participants with non-hodgkin's lymphoma","id":"OG001","title":"Cohort 4"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma","type":"SECONDARY","unitOfMeasure":"Months"}